Skip to main
SLDB

Solid Biosciences (SLDB) Stock Forecast & Price Target

Solid Biosciences (SLDB) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 55%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates for the treatment of neuromuscular and cardiac diseases. Their lead candidate, SGT-003, has shown consistent biomarker and safety data in clinical trials, and the company is anticipating initial clinical data in the second half of 2026 and potential approval in late-2028. With a strong pipeline of potential treatments and a recent private placement that extended their cash runway to 1H28, Solid Biosciences has a positive outlook for long-term success in the gene therapy market. However, there are potential risks, including the complex regulatory pathway for gene therapies and the competitive landscape for treating rare diseases like DMD.

Bears say

Solid Biosciences is focusing primarily on gene therapy products for the treatment of neuromuscular and cardiac diseases, which faces challenges for long-term benefits and risks. Additionally, there is a risk for manufacturing delays, as well as setbacks in clinical trials and regulatory approval. Competitor companies and a potential narrower indication for approval could also impact the company's success.

Solid Biosciences (SLDB) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 55% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solid Biosciences (SLDB) Forecast

Analysts have given Solid Biosciences (SLDB) a Buy based on their latest research and market trends.

According to 11 analysts, Solid Biosciences (SLDB) has a Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solid Biosciences (SLDB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.